Analyzing Patheon (PTHN) and Its Competitors
Patheon (NYSE: PTHN) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Patheon to similar businesses based on the strength of its dividends, institutional ownership, risk, profitability, valuation, earnings and analyst recommendations.
Insider & Institutional Ownership
0.7% of Patheon shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.1% of Patheon shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Patheon and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Patheon||$1.87 billion||$31.70 million||46.64|
|Patheon Competitors||$8.17 billion||$1.09 billion||128.85|
Patheon’s peers have higher revenue and earnings than Patheon. Patheon is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for Patheon and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Patheon currently has a consensus target price of $33.60, indicating a potential downside of 3.95%. As a group, “Pharmaceuticals” companies have a potential upside of 20.86%. Given Patheon’s peers stronger consensus rating and higher probable upside, analysts clearly believe Patheon has less favorable growth aspects than its peers.
This table compares Patheon and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Patheon has a beta of 2.69, meaning that its share price is 169% more volatile than the S&P 500. Comparatively, Patheon’s peers have a beta of 34.66, meaning that their average share price is 3,366% more volatile than the S&P 500.
Patheon peers beat Patheon on 10 of the 13 factors compared.
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Receive News & Ratings for Patheon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon and related companies with Analyst Ratings Network's FREE daily email newsletter.